Bio/Pharma News

Shire Acquires Foresight Biotherapeutics for $300 Million

August 04, 2015

The acquisition strengthens Shire’s ophthalmics portfolio.

Shire Proposes Combination with Baxalta

August 04, 2015

Shire takes its offer for an all-stock transaction to combine with Baxalta to shareholders after Baxalta declines to discuss the proposal.

FDA Approves First 3D-Printed Drug Product

August 03, 2015

PTSM: Pharmaceutical Technology Sourcing and Management

Aprecia Pharmaceutical’s SPRITAM levetiracetam gains FDA approval for the treatment of epilepsy.

Mumbai-based Lupin Goes On Spending Spree

July 31, 2015

Lupin acquires businesses in Germany, the US, Russia, Brazil, and South Africa.

arGEN-X Partners with University of Bern to Develop Combination Cancer Therapies

July 30, 2015

ARGX-110-based combination therapies have demonstrated potential in treatment-resistant cancers.

Novartis Creates Biotech Spin-Off Mereo

July 30, 2015

The new biotech company, Mereo, is based in the United Kingdom, and kicks off with three mid-stage assets from Novartis.

Hikma Acquires Boehringer’s US Generic Drug Business for $2.65 Billion

July 29, 2015

The purchase will strengthen Hikma’s position in the US generic drug market.

Sanofi and Regeneron Form Immuno-Oncology Pact

July 29, 2015

The collaboration will focus on advancing bi-specific antibodies that target hematologic and solid cancers, either as monotherapies or in combination regimens with other immune modulating treatments.

Teva Withdraws Mylan Offer, Agrees to Acquire Allergan’s Generics Business

July 27, 2015

The deal to acquire Allergan’s generic-drug business is valued at $40.5 billion.

FDA Approves Praluent, the First PCSK9 Inhibitor in the US

July 27, 2015

FDA approved the drug for a more narrow indication in the US than did EMA for Repatha, Praluent’s fiercest competitor.